by Team Small News | Dec 10, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals Inc. has issued a recall of over 11,100 bottles of its blood pressure medication, Ziac, due to potential cross-contamination with another drug. The medication, which is used to treat high blood pressure, also known as hypertension, may contain... by Team Small News | Dec 4, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals has significantly expanded its presence in the “High Latin America” region, which includes Mexico, Colombia, Ecuador, Peru, Central America, and the Caribbean, over the past four years. The company’s growth in this region has... by Team Small News | Dec 2, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals, a prominent drugmaker, has successfully completed a pre-approval inspection by the U.S. Food and Drug Administration (FDA) at its formulations manufacturing facility in Chhatrapati Sambhajinagar, Maharashtra. The inspection, which took place...
by Team Small News | Nov 12, 2025 | Glenmark, Pharma, Zydus
Zydus Lifesciences and Glenmark Pharmaceuticals have both received approvals from China’s National Medical Products Administration (NMPA) for their respective products. Zydus Lifesciences has been granted approval for Venlafaxine Extended-Release (ER) Capsules,... by Team Small News | Nov 5, 2025 | Glenmark, Pharma
The Leander Paes-Samanta Sports Academy has partnered with the Glenmark Aquatic Foundation to promote sports development at Kalinga Institute of Industrial Technology (KIIT) and Kalinga Institute of Social Sciences (KISS) in Bhubaneswar, Odisha. This collaboration... by Team Small News | Oct 25, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Ropivacaine Hydrochloride Injection USP, a generic version of Naropin Injection, in November 2025. The new product will be available in three strengths: 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5...